i think so. ....since 2010 zevalin has been guided to become $300m/year in "a few years". After 4 years run rate is still less than $40m..
Back in fall of 2012, Fusilev was guided to grow from its 2012 sales . In march 2013 this guidance was revised downwards by greater than 45%
Hence a phase 3 trial failed drug APAZ, is just that. Don't listen to much of anything on this, unless you see successful phase 3 data. everything else is bs
Yes it is a bait... Raj always uses baits to get new investors:
* Satraplatin has 500mio USD potential
* Zevalin is a 300mio drug easily
* Fusilev will grow, i will prove the naysayers wrong
The baits now are Melphalan, Marqibo and Apaziquone
You still mad bro ?
Instead of selling your 100 shares @ 8 you could have bout 100 more at that price and now be even.
base_ball_fanatic = joesolomon = sherrysgone = otisthepig = mnm ?